Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
During health secretary nominee Robert F. Kennedy Jr.'s Jan. 29 Senate confirmation hearing, Sen. Elizabeth Warren, D-Mass., ...
Amid scrutiny over Robert F. Kennedy Jr.'s pledge to divest his financial stake in vaccine lawsuits to his family, legal ...
Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.
The drug company’s outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit shares.
This update provides insights into critical global health developments, including Merck's halt on Gardasil shipments to China ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results